
The Danish company Chemometec will – to an even larger extent than previously – be looking towards the other side of the Atlantic for success, announces company CEO Martin Glensbjerg.
“What’s working especially well for us is development in the US. We see a great deal of direct sales of our cell-count product through our subsidiary,” the CEO explains to Medwatch and elaborates:
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app